文献速递毛发、甲与色素性疾病

头皮低温预防化疗性脱发的对照临床试验综述

Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-11-24

本文综述了评估头皮低温预防化疗性脱发的对照与随机对照临床试验。分析显示,头皮低温在对照试验中使脱发发生率降低2.7倍,在随机对照试验中降低3.9倍,表明其是有效的预防措施。

要点

  • 头皮低温可有效降低化疗性脱发发生率,对照试验降低2.7倍,随机对照试验降低3.9倍。
  • 现有研究多为非对照或小样本,随机对照数据有限,尚无明确的最佳使用指南。
  • 头皮低温仍是预防化疗性脱发最广泛使用的方法,相关设备已获FDA许可。

核心结论

  • 头皮低温是预防化疗性脱发的有效措施,可使脱发发生率在对照试验中降低2.7倍、随机对照试验中降低3.9倍。

研究设计与样本

  • 本文为文献综述,纳入并对比评估头皮低温预防化疗性脱发的对照临床试验(CCTs)和随机对照临床试验(RCTs)。

主要发现

  • 头皮低温在CCTs中使化疗性脱发发生率降低2.7倍,在RCTs中降低3.9倍。
  • 现有研究因化疗方案、冷却技术、给药方式和患者因素差异导致结果不一,且多为非对照或小样本研究。

关键数值与推荐

  • 化疗性脱发影响65%接受癌症化疗的患者。

临床怎么用

  • 头皮低温可用于预期化疗后脱发的管理,但最佳使用方案尚无明确指南。

局限性

  • 现有研究多为非对照或小样本,随机对照数据有限,缺乏明确的最佳头皮冷却使用指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapy-induced alopecia (CIA) is a temporary, yet psychologically devastating form of hair loss that affects 65% of patients receiving cancer chemotherapy. In the 1970s, scalp hypothermia was introduced as a preventative measure against the development of CIA. Numerous studies provide evidence for the effectiveness of scalp cooling to prevent CIA, although results varied because of differences in chemotherapy regimen, cooling technique, mode of administration and patient factors. However, many of the existing studies are uncontrolled or consist of small sample sizes, and data from randomized, randomized studies are limited. To date, no clear guidelines have been established for optimum scalp cooling use as a treatment modality and its efficacy remain unknown. Nonetheless, scalp cooling remains the most widely utilized method for the prevention of CIA, and in December 2015, the United States Food and Drug Administration (FDA) cleared the DigniCap® Scalp Cooling System (Dignitana AB, Sweden) for marketing and the Orbis from Paxman® Coolers Ltd. received clearance in 2017. This literature review is one of the first to provide up-to-date review and side-by-side comparisons of controlled and randomized clinical trials (CCTs and RCTs) evaluating scalp hypothermia for the prevention of CIA. Our analyses of CCTs and RCTs to date show that scalp hypothermia is effective in reducing the occurrence rate of CIA, by 2.7-fold in the CCTs and 3.9-fold in the RCTs. These results suggest that scalp hypothermia represents an effective preventative measure for CIA, and provide guidance for management of anticipated alopecia following chemotherapy and for future investigations.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Shah VV, Wikramanayake TC, DelCanto GM, et al. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials. J Eur Acad Dermatol Venereol. 2017. PMID: 28976026. doi:10.1111/jdv.14612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。